Vertex Pharmaceuticals Incorporated (BIT:1VRTX)

Market Cap	94.16B
Revenue (ttm)	9.99B
Net Income (ttm)	3.13B
Shares Out	n/a
EPS (ttm)	12.12
PE Ratio	30.06
Forward PE	20.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Average Volume	5
Open	372.10
Previous Close	365.60
Day's Range	372.10 - 376.55
52-Week Range	316.00 - 482.10
Beta	n/a
RSI	58.55
Earnings Date	Nov 3, 2025

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1989
• Employees: 6,100
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1VRTX

Financial Performance

Financial numbers in USD